NeuBase Therapeutics with ticker code (NBSE) have now 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 18 and 15 and has a mean target at 16.8. With the stocks previous close at 10.46 this now indicates there is a potential upside of 60.6%. The day 50 moving average is 9.48 and the 200 day moving average is 8.47. The company has a market cap of $236m. Company Website: http://www.neubasetherapeutics.com
NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington’s disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
